

Latuda[®] (lurasidone) – First-time generic

- On February 20, 2023, [Accord](#), [Amneal](#), [Dr. Reddy's](#), [MSN/Novadoz](#), [Sun](#), [Alkem/Ascend](#), [Zydus](#), and [Lupin launched](#) AB-rated generic versions of Sunovion's [Latuda \(lurasidone\)](#) tablets.
- Latuda is approved for:
 - Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia
 - Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression)
 - Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression).
- According to IQVIA, Latuda had estimated annual sales of \$4.2 billion in the U.S.